EA201690645A1 - НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK - Google Patents

НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK

Info

Publication number
EA201690645A1
EA201690645A1 EA201690645A EA201690645A EA201690645A1 EA 201690645 A1 EA201690645 A1 EA 201690645A1 EA 201690645 A EA201690645 A EA 201690645A EA 201690645 A EA201690645 A EA 201690645A EA 201690645 A1 EA201690645 A1 EA 201690645A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
pirrolo
pyrimidinyl
pyridine
compounds
Prior art date
Application number
EA201690645A
Other languages
English (en)
Other versions
EA029595B1 (ru
Inventor
Джордж Хинд
Патриция Тисселли
Дэвид Эдвард Кларк
Януш Йозеф Кулаговский
Калум Маклеод
Самьюэль Эдвард Манн
Терри Аарон Панчал
Стефен Колин Прайс
Джон Гари Монтана
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201690645A1 publication Critical patent/EA201690645A1/ru
Publication of EA029595B1 publication Critical patent/EA029595B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим средствам, применимым для терапии и/или профилактики у млекопитающего, и, в частности, к ингибиторам NF-κB-индуцирующей киназы (NIK, также известной как МАРЗК14), применимым для лечения заболеваний, таких как рак, воспалительные нарушения, нарушения метаболизма и аутоиммунные нарушения. Настоящее изобретение также направлено на фармацевтические композиции, содержащие такие соединения, на способы получения таких соединений и композиций и на применение таких соединений или фармацевтических композиций для предупреждения или лечения заболеваний, таких как рак, воспалительные нарушения, нарушения метаболизма, в том числе ожирение и диабет, и аутоиммунные нарушения.
EA201690645A 2013-09-26 2014-09-25 НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-с]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK EA029595B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13186139 2013-09-26
EP14176121 2014-07-08
PCT/EP2014/070484 WO2015044267A1 (en) 2013-09-26 2014-09-25 NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS

Publications (2)

Publication Number Publication Date
EA201690645A1 true EA201690645A1 (ru) 2016-08-31
EA029595B1 EA029595B1 (ru) 2018-04-30

Family

ID=51619194

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690645A EA029595B1 (ru) 2013-09-26 2014-09-25 НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-с]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK

Country Status (15)

Country Link
US (1) US10005773B2 (ru)
EP (1) EP3071566B1 (ru)
JP (1) JP6402179B2 (ru)
KR (1) KR102317334B1 (ru)
CN (1) CN105579451B (ru)
AU (1) AU2014327233B2 (ru)
BR (1) BR112016005914A2 (ru)
CA (1) CA2922753C (ru)
EA (1) EA029595B1 (ru)
ES (1) ES2804595T3 (ru)
HK (1) HK1224295A1 (ru)
IL (1) IL244706B (ru)
MX (1) MX2016003861A (ru)
TW (1) TWI704146B (ru)
WO (1) WO2015044267A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
CA2960567C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Thienopyrimidine derivatives as nik inhibitors
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors
KR102499862B1 (ko) 2014-10-23 2023-02-13 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸 유도체
EP3209663B1 (en) 2014-10-23 2018-12-12 Janssen Pharmaceutica N.V. New pyrazolopyrimidine derivatives as nik inhibitors
KR20180100441A (ko) 2016-01-22 2018-09-10 잔센파마슈티카엔.브이. Nik 억제제로서 신규 치환된 시아노인돌린 유도체
AU2017208555B2 (en) 2016-01-22 2021-03-18 Janssen Pharmaceutica Nv New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
JP6936815B2 (ja) 2016-06-30 2021-09-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体
US20190119299A1 (en) * 2016-06-30 2019-04-25 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
JP7140751B2 (ja) * 2016-08-24 2022-09-21 エフ．ホフマン－ラ ロシュ アーゲー ２－アザビシクロ［３．１．０］ヘキサン－３－オン誘導体及び使用方法
EP3504192B1 (en) * 2016-08-24 2022-04-06 F. Hoffmann-La Roche AG 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
BR112021023796A2 (pt) 2019-05-31 2022-02-08 Janssen Pharmaceutica Nv Inibidores de moléculas pequenas de quinase indutora de nf-capab
CN113816957B (zh) * 2021-10-29 2023-04-07 浙江工业大学 4-(7-氮杂吲哚)-2-氨基嘧啶类化合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990061B2 (ja) * 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
EP1756103A2 (en) 2004-04-26 2007-02-28 Pfizer, Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
AR056786A1 (es) * 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
CA2728767A1 (en) 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
CN102143746A (zh) 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CA2827161A1 (en) 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
TWI663166B (zh) * 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
KR102499862B1 (ko) 2014-10-23 2023-02-13 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸 유도체
EP3209663B1 (en) 2014-10-23 2018-12-12 Janssen Pharmaceutica N.V. New pyrazolopyrimidine derivatives as nik inhibitors
CA2960567C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Thienopyrimidine derivatives as nik inhibitors
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors

Also Published As

Publication number Publication date
TW201602104A (zh) 2016-01-16
CN105579451A (zh) 2016-05-11
EP3071566A1 (en) 2016-09-28
AU2014327233A1 (en) 2016-03-10
ES2804595T3 (es) 2021-02-08
EP3071566B1 (en) 2020-04-15
KR20160058814A (ko) 2016-05-25
US20160257679A1 (en) 2016-09-08
CN105579451B (zh) 2017-10-27
IL244706B (en) 2021-02-28
KR102317334B1 (ko) 2021-10-26
BR112016005914A2 (pt) 2017-08-01
HK1224295A1 (zh) 2017-08-18
US10005773B2 (en) 2018-06-26
AU2014327233B2 (en) 2018-03-01
CA2922753C (en) 2021-08-17
EA029595B1 (ru) 2018-04-30
JP6402179B2 (ja) 2018-10-10
CA2922753A1 (en) 2015-04-02
TWI704146B (zh) 2020-09-11
IL244706A0 (en) 2016-04-21
MX2016003861A (es) 2016-07-26
JP2016531868A (ja) 2016-10-13
WO2015044267A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
EA201690645A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK
EA201690657A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 3-(1H-ПИРАЗОЛ-4-ИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
EA201790904A1 (ru) Новые производные пиразола в качестве ингибиторов nik
EA201592033A1 (ru) 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА
EA201790908A1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
EA201790688A1 (ru) Новые соединения в качестве ингибиторов nik
EA201790907A1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik
MX363457B (es) Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1).
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
PH12016502353A1 (en) Pharmaceutical composition
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
TW201613577A (en) Pharmaceutical combinations
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
IN2014KN00849A (ru)
EA201891687A9 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов
MY198316A (en) Piperidin-4-YL Azetidine Derivatives as JAK1 Inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM